271 related articles for article (PubMed ID: 26020804)
21. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
22. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation.
Vaid M; Sharma SD; Katiyar SK
Carcinogenesis; 2010 Nov; 31(11):2004-11. PubMed ID: 20823108
[TBL] [Abstract][Full Text] [Related]
23. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.
Lee B; Kim CH; Moon SK
FEBS Lett; 2006 Oct; 580(22):5177-84. PubMed ID: 16962592
[TBL] [Abstract][Full Text] [Related]
24. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
25. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
26. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
27. Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function.
Pan J; Zhang Q; Liu Q; Komas SM; Kalyanaraman B; Lubet RA; Wang Y; You M
Cancer Prev Res (Phila); 2014 Nov; 7(11):1149-59. PubMed ID: 25245764
[TBL] [Abstract][Full Text] [Related]
28. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
[TBL] [Abstract][Full Text] [Related]
30. Honokiol targets mitochondria to halt cancer progression and metastasis.
Pan J; Lee Y; Wang Y; You M
Mol Nutr Food Res; 2016 Jun; 60(6):1383-95. PubMed ID: 27276215
[TBL] [Abstract][Full Text] [Related]
31. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
[TBL] [Abstract][Full Text] [Related]
32. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
[TBL] [Abstract][Full Text] [Related]
33. Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells.
Chen XR; Lu R; Dan HX; Liao G; Zhou M; Li XY; Ji N
Int J Oral Sci; 2011 Jan; 3(1):34-42. PubMed ID: 21449214
[TBL] [Abstract][Full Text] [Related]
34. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells.
Lu CH; Chen SH; Chang YS; Liu YW; Wu JY; Lim YP; Yu HI; Lee YR
Pharmacol Res; 2017 Jan; 115():288-298. PubMed ID: 27940017
[TBL] [Abstract][Full Text] [Related]
35. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction.
Huang JS; Yao CJ; Chuang SE; Yeh CT; Lee LM; Chen RM; Chao WJ; Whang-Peng J; Lai GM
BMC Cancer; 2016 Mar; 16():245. PubMed ID: 27012679
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
37. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
39. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
[TBL] [Abstract][Full Text] [Related]
40. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
